Good MorningThe equity market extended Wednesday's rebound on Thursday but might be headed nowhere fast. The S&P 500 advanced about 0.75% at the session's high but remains below critical resistance points, nearing overbought conditions without setting a new high. Because of elevated volatility and uncertainty, the market will likely top out soon and revert to the bottom of the recent range. Among the catalysts for the move is the upcoming FOMC meeting scheduled for Tuesday and Wednesday of next week.
Economic data and market expectations cause the volatility. On the one hand, inflation is cooling, but the outlook for the Fed to lower interest rates is also cooling. The critical detail is that the FOMC will lower interest rates this year, but likely at a slower pace than the market would like. The takeaway for investors is that FOMC is threading the needle regarding the soft landing, economic conditions remain healthy, and a broader stock market rally should follow. Featured: Americans are unlocking their IRA/401k (Ad) 
|
Markets | |
Exchange-traded funds (ETFs) are typically considered to be suitable investments for retail investors who have a hands-off approach. The built-in portfolio diversity inherent to many of these funds and the ability to hand over management of a fund's basket of securities to a team of professional m... Read the Full Story |
|
From Our Partners | | Gold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up to $1,127 a month from a little-known 15 dollar fund built around it.
This fund turns gold's price swings into cash, paid out every single Friday. | | See exactly how this weekly-paying gold fund works today |
|
Markets | |
The past few years have been turbulent for Chinese companies listed on U.S. exchanges. Their stock prices have floundered despite major U.S. indexes reaching new heights. This disconnect is primarily driven by escalating political tensions between the U.S. and China and a lack of clarity regarding... Read the Full Story |
|
Technology | |
Tech device nerds are buzzing. Apple (NASDAQ: AAPL) just unveiled its new, AI-capable iPhone 16s. However, the excitement isn’t just around the devices themselves; investors are also talking. Wedbush raised their price target immediately after the official event displaying the new devices, w... Read the Full Story |
|
From Our Partners | | The Department of Justice recently argued in court that cash isn't property - a claim that could reshape how much control you actually have over the money in your bank account.
If your balance isn't legally guaranteed to be yours, who really controls it? Three strategies may help you prepare before any restrictions take hold. | | Download the free guide to help protect your bank savings today |
|
Healthcare | |
Summit Therapeutics Inc. (NASDAQ: SMMT) has seen a meteoric rise this month, surging over 106% after releasing positive clinical trial results for its experimental cancer therapy. Year-to-date, the stock is up a staggering 769%.
This sharp uptick in share price was driven by the results of a Pha... Read the Full Story |
|
Markets | |
Treasury bonds are the cornerstone of many investment portfolios, offering investors a safe and reliable way to invest in the U.S. government. These long-term debt securities are backed by the full faith and credit of the U.S. government, making them one of the most secure investment options avail... Read the Full Story |
|
From Our Partners | | Deutsche Bank's research team projects gold could reach $8,000 per ounce by 2031, roughly 80% above current prices, as central banks continue shifting reserves away from the U.S. dollar.
It's not alone: JPMorgan sees $6,000 by year-end, Goldman Sachs $5,400, and UBS $5,900 by late 2026 - three major banks already forecasting gold above $5,000.
For retirees holding savings mostly in dollars, cash, or bonds, this shift could matter more than most realize. | | Download the free Wealth Protection Guide to see how you're positioned |
|
Technology | |
Arm Holdings (NASDAQ: ARM) is a renowned semiconductor IP designer whose chips power billions of devices worldwide. Arm has recently caught the eye of investors, surging in value on the back of a strong endorsement from Morgan Stanley (NYSE: M). The investment bank has declared Arm its "Top Pick,"... Read the Full Story |
|
Communication Services | |
Roblox (NYSE: RBLX) has become one of the world’s most popular video games over the past several years. Based on average monthly users among PC games, the game ranked second in July this year, only behind Minecraft. Since 2018, the company has managed to nearly 10x its revenues.
However, ... Read the Full Story |
|
Markets | |
After a prolonged consolidation and downtrend following the pandemic-driven surge, the biotechnology sector is readying for a potential breakout and shifting its narrative. Represented by the iShares Biotechnology ETF (NASDAQ: IBB), the sector has turned a significant corner, with previous resista... Read the Full Story |
|
Consumer Discretionary | |
Dave & Buster’s (NASDAQ: PLAY) stock surged more than 10% after its Q2 earnings release because the narrative went something like this: the company is growing, but growth is weak, and expectations are missed. However, the miss was tepid, creating a “meh” reaction from the mar... Read the Full Story |
|
Technology | |
Whenever investors think of how to get exposure to a stock’s direction, they typically only think of buying or selling a stock. However, professionals tend to delve a bit deeper into their views through the use of stock options. These options give traders the advantage of leverage to bet on ... Read the Full Story |
|
Friday's Early Bird Stock Of The Day AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. | | View Today's Stock Pick |
|
